FDA expected to authorize COVID-19 vaccine booster shots for immunocompromised
The Food and Drug Administration is expected to authorize COVID-19 booster shots for those who are immunocompromised.
If approved, immunocompromised people would be able to get the booster dose before it is offered to the public at large.
Companies like Moderna and Pfizer are pushing for the third shot because they say that COVID antibodies need to be replenished.
The third shot may differ in dosage and would likely be taken six months from the time of the second vaccine shot.
Health officials say there's a concern for those who are immunocompromised because even if vaccinated, their bodies may not mount an effective immune response to the coronavirus.
COVID RESOURCES: COVID-19 vaccine resources and case data
SEARCH FOR A CURE: Statistics and State Resources
EXPLAINER: The CDC's new mask guidelines
New Jersey resident Chris Treubert, of Neptune, has been living with Stage 4 pancreatic cancer. He had his second shot of the Moderna vaccine in February – six months ago. As he deals with pain management every day, he says he is excited to hear about the booster.
“I’m definitely looking forward to it. A little anxious. But definitely don’t have any issues with the first and second shot. There were no side effects for me. I got the Moderna and I welcome the third shot,” Treubert says.
Treubert gets his treatment through Memorial Sloan Kettering. He says he expects to hear from his doctors there about setting a time frame for the booster.
The Centers for Disease Control and Prevention estimates that about 9 million people in the United States are immunocompromised.